The European League Against Rheumatism (EULAR) has launched a European paediatric and adult database to monitor and report outcomes of COVID-19 in patients with rheumatic and musculoskeletal diseases (RMDs). The initiative is supported by the Global Rheumatology Alliance and the Pediatric Rheumatology European Society.
EULAR will provide the rheumatology community with regularly updated information on reported cases in patients with RMD, including numbers of cases by country and the number of cases by treatment.
Dr Pedro Machado, Associate Professor & Consultant Rheumatologist at University College London and Chair of the EULAR Standing Committee of Epidemiology and Health Services Research, says: “There is an urgent need to understand outcomes of patients who acquire COVID-19 and are receiving steroids, synthetic or biologic disease-modifying anti-rheumatic drugs, and non-steroidal anti-inflammatory drugs. This will help guide rheumatologists and other clinicians such as specialist nurses in advising and caring for their patients.”
EULAR is encouraging clinicians from across Europe to report all cases of COVID-19 in their rheumatology patients.
To avoid duplication, only European cases should be reported to EULAR. Cases reported to national databases should not be duplicated in the EULAR database. Non-European EULAR countries should report cases to the EULAR database rather than to the US-based database.